 Efficacy toxicity pentostam Panamanian mucosal leishmaniasis World Health Organization WHO treatment mucosal leishmaniasis disease due Leishmania braziliensis panamensis Disease population nasal mucosa patient septal perforation patients mg antimony form Pentostam kg day days patients therapy month follow-up patients therapy lesions month follow-up patients therapy liver enzyme elevations conjunction EKG abnormalities musculoskeletal complaints none patients study patients mild mucosal leishmaniasis WHO curative patients treatment patients